Home » Newsletters » BioWorld Science

BioWorld Science

June 12, 2012

View Archived Issues

Novel RANKL inhibitor reduces bone resorption in vivo

Researchers disclose lixisenatide data from GetGoal and other trials

U.S. researchers present new low-cost metabolic disease model

Lycera generates novel ROR-gamma antagonists

Chinese researchers develop new vaccines

Daiichi Sankyo presents new diacylglycerol O-acyltransferase inhibitors

Bristol-Myers Squibb reports preparation of novel mGlu5 receptor modulators

Gedeon Richter patents novel bradykinin B1 receptor antagonists

Avanir Pharmaceuticals to begin phase II AVP-923 study

Tengion reports continued progress with Neo-Urinary Conduit

Phase I and II trials assess Gradalis cancer vaccines

U.S. study reveals microRNAs with prognostic significance in kidney cancer

Cara Therapeutics reports results from phase II CR-845 trial

Ubidecarenone investigated for oncolytic activity

Ampio Pharmaceuticals schedules pre-IND meeting for Optina

BioSante Pharmaceuticals plans new phase III LibiGel trials

Protalix receives milestone payment for Elelyso approval

DSMB issues recommendation on phase III program for SFP-iron replacement

Astellas and DNDi launch drug discovery collaboration for three neglected tropical diseases

FDA approves companion diagnostics for Genentech anticancer drug

Stiefel acquires worldwide rights to Toctino

GE Healthcare to provide imaging agent to Australian government for Alzheimer's study

Genzyme files applications for approval of Lemtrada

Promising preclinical data reported on BT-2111

New ENTPD5 inhibitors developed by University of Texas System

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...